Disclosed is the Use of an anti-VEGF antibody, or antigen-binding fragment thereof, in the manufacture of a medicament for reducing or preventing occurrence of a benign, pre- cancerous, or non-metastatic cancer in a subject with a family history of cancer, polyps, or an inherited cancer syndrome, wherein the subject has never had clinically detectable cancer, and wherein the anti-VEGF antibody or antigen-binding fragment thereof blocks VEGF binding to more than one VEGF receptor.
